Social Media
The Social Media Questions Pharma Companies Should be Asking
For pharma companies, entering the social media scene is not as simple as just creating a Facebook page or learning how to tweet in 140 characters or less. Social media poses a regulatory and litigation maze that must be carefully navigated. Here, Mathew dos Santos and Lori Leskin provide some insight into the most pressing questions companies are, or should be, asking about social media...Read more
Marketing Communications
Lack of Multichannel Confidence: A Step on the Road to Digital Maturity
It would be easy to see this year’s Across Health Multichannel Barometer survey results as further evidence that pharma is doomed to never get digital. But, writes Peter Houston, there is optimism that the results are a sign of the industry’s digital maturity ...Read more
Optimize Your Marketing for Drug Development Services: SCORR Marketing, a performance leader in marketing for the drug development services industry, performed an in-depth performance assessment that gives you an inside look at how companies in your industry are defining their marketing programs and allocating their budgets. Access the Report Now>>
Specialty Drugs
Three Challenges to the Specialty Business Model
Drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Emily O’Connor, Jillian Scaife, and Ryan P. Million outline three key challenges to the focus on specialty indications that are particularly critical for drug companies ...Read more
Technology
What Apple’s HealthKit Announcement Means for Pharma
Every good healthcare executive should be aware of at least two big implications of Apple’s newly unveiled “HealthKit”, a developer’s toolbox that allows makers of health and medical devices to more seamlessly integrate their offerings with Apple’s newest mobile operating system, iOS8. Bill Drummy reports ...Read more
Regulatory
What Does ‘Off-Label’ Mean in 2014?
Although drug companies make an enormous effort to obtain an FDA approval with a very specific indication, it always comes as a bit of a shock to learn that the medical community is not only using the product for that hard to achieve FDA approval — but also for several other non-approved indications. Tom Norton reports ...Read more
Special Feature
Pharm Exec’s Top 50 Pharma Companies
The vigorous return of M&A activity to biopharmaceuticals this year begs the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system? Our latest annual iteration of the Pharma 50 rankings confirms that the answer to this is ‘no’ ...Read more |
